These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 18508540)
1. Antisense DNA and RNA agents against picornaviruses. Lim T; Yuan J; Zhang HM; Sall A; Liu Z; Su Y; Yang D Front Biosci; 2008 May; 13():4707-25. PubMed ID: 18508540 [TBL] [Abstract][Full Text] [Related]
2. Selective inhibitors of picornavirus replication. De Palma AM; Vliegen I; De Clercq E; Neyts J Med Res Rev; 2008 Nov; 28(6):823-84. PubMed ID: 18381747 [TBL] [Abstract][Full Text] [Related]
3. Antisense tumor therapy (a dream under construction). Kopper L; Kovalszky I In Vivo; 1994; 8(5):781-6. PubMed ID: 7727725 [TBL] [Abstract][Full Text] [Related]
5. Strand-specific silencing of a picornavirus by RNA interference: evidence for the superiority of plus-strand specific siRNAs. Schubert S; Rothe D; Werk D; Grunert HP; Zeichhardt H; Erdmann VA; Kurreck J Antiviral Res; 2007 Mar; 73(3):197-205. PubMed ID: 17112603 [TBL] [Abstract][Full Text] [Related]
6. [The application of antisense technology in ophthalmology]. Guo Y; Ge J Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046 [TBL] [Abstract][Full Text] [Related]
7. RNA as a target for developing antivirals. McKnight KL; Heinz BA Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917 [TBL] [Abstract][Full Text] [Related]
8. Antisense technology for cancer therapy: does it make sense? Carter G; Lemoine NR Br J Cancer; 1993 May; 67(5):869-76. PubMed ID: 8494718 [No Abstract] [Full Text] [Related]
9. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents. Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650 [TBL] [Abstract][Full Text] [Related]
10. Strategies to identify potential therapeutic target sites in RNA. Lützelberger M; Kjems J Handb Exp Pharmacol; 2006; (173):243-59. PubMed ID: 16594619 [TBL] [Abstract][Full Text] [Related]
11. RNAi: a novel antisense technology and its therapeutic potential. Dallas A; Vlassov AV Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063 [TBL] [Abstract][Full Text] [Related]
13. Antisense and sensibility. Dove A Nat Biotechnol; 2002 Feb; 20(2):121-4. PubMed ID: 11821852 [No Abstract] [Full Text] [Related]
14. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Wagner A; Bock CT; Fechner H; Kurreck J Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598 [No Abstract] [Full Text] [Related]
15. DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes. Fokina AA; Stetsenko DA; François JC Expert Opin Biol Ther; 2015 May; 15(5):689-711. PubMed ID: 25772532 [TBL] [Abstract][Full Text] [Related]
16. Prospects for nucleic acid-based therapeutics against hepatitis C virus. Lee CH; Kim JH; Lee SW World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620 [TBL] [Abstract][Full Text] [Related]
18. [Pleconaril, a new aniviral drug with activity against picornavirus]. Reina J; Ballesteros F Rev Esp Quimioter; 2000 Sep; 13(3):257-62. PubMed ID: 11086273 [No Abstract] [Full Text] [Related]
19. Antisense oligonucleotides as therapeutic agents. Alama A; Barbieri F; Cagnoli M; Schettini G Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660 [TBL] [Abstract][Full Text] [Related]
20. Killing the messenger: antisense DNA and siRNA. Nesterova M; Cho-Chung YS Curr Drug Targets; 2004 Nov; 5(8):683-9. PubMed ID: 15578949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]